Fig. 1
From: Circulating miR-200a is a novel molecular biomarker for early-stage renal cell carcinoma
The expression levels of the examined miRNAs in serum in the training and validation phase. a-c The relative expression levels of serum miR-200a (a), miR-200b (b), and miR-200c (c) in the training phase. d, e The relative expression levels of serum miR-200a in the validation phase (D) and in the combined two phases (e). f The relative expression levels of serum miR-200a in RCC cases at different stages enrolled in the training and validation phases. The relative expression levels of miRNAs were normalized to let-7d/g/i and calculated using the 2-ΔCq method. Each point represents the mean of triplicate samples. Each P-value was derived from a nonparametric Mann–Whitney U-test. *P < 0.05; ***P < 0.001